Eon and CancerIQ Join Forces to Enhance Patient Detection and Care Completion

Partnership Overview

Eon, recognized as a leader in early detection and incidental findings technology, has announced a strategic partnership with CancerIQ, a platform specialized in cancer risk identification. This collaboration aims to streamline the processes for health systems to identify at-risk patients and manage their follow-up care effectively.

Historically, health systems have faced significant challenges in keeping track of at-risk patients through various healthcare stages. Many high-risk patients fail to access imaging services, as their personal or family histories that qualify them for screenings often go unrecognized. CancerIQ addresses this issue by identifying eligible patients within the broader population and actively engaging them in the screening process.

Additionally, even when patients undergo imaging, many incidental findings—unexpected abnormalities identified during scans—often go unaddressed due to inadequate follow-up. Eon contributes to resolving this issue by systematically identifying such findings and participating in the care management process to ensure appropriate follow-up occurs.

Synergistic Capabilities

Through this partnership, Eon's health system clients will gain access to CancerIQ's comprehensive risk assessment capabilities, which can be implemented either during clinical visits or via at-home assessments. This feature will help in determining which patients meet the guideline criteria for necessary screenings or ongoing surveillance.

By leveraging CancerIQ's expertise in guiding patients through tests such as low-dose CT scans, breast MRIs, colonoscopies, or even genetic testing, Eon can focus on operational management within the imaging workflow. Eon’s platform excels at pinpointing actionable findings within radiology reports, simplifying the tracking and follow-up processes for care teams.

Improving Outcomes

The ultimate goal of this partnership is to enhance early cancer detection by ensuring that patients receive appropriate screenings without overwhelming care teams with additional complexity. As Dr. Akrum Alzubaidi, CEO and Founder of Eon, states, “Our focus at Eon has always been to ensure that no patient falls through the cracks.” CancerIQ’s efficient identification and patient engagement methods align seamlessly with Eon's existing efforts, creating a comprehensive approach to patient care.

Both organizations boast impressive result metrics. CancerIQ has claimed a remarkable 4.2x increase in supplemental screenings and an average ROI of 8.9x for its health system clients. Similarly, Eon has seen follow-up completion rates exceed 90%, alongside substantial increases in downstream diagnostic examinations. The combined efforts of Eon and CancerIQ aim to minimize the number of at-risk patients who fall through the cracks, thereby boosting the completion rates of guideline-concordant screenings without necessitating an increase in staff among already burdened care teams.

Conclusion

The collaboration between Eon and CancerIQ represents a significant step forward in cancer detection and care management. By combining their strengths and technologies, the two companies are poised to create a unified solution that empowers health systems to deliver timely and thorough care to at-risk patients. This partnership not only fortifies the health care infrastructure but also embodies a commitment to improving patient outcomes and enhancing the overall effectiveness of cancer screening processes.